Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home

Lucas, Mary; Hugh-Jones, Ken; Welby, Angela; Misbah, Siraj; Spaeth, Peter; Chapel, Helen (2010). Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home. Journal of clinical immunology, 30 Suppl 1, S84-S89. New York, N.Y.: Springer 10.1007/s10875-010-9400-y

Preview

Text s10875-010-9400-y.pdf - Published Version Available under License Publisher holds Copyright. Download (674kB) | Preview

The Oxford Programme for Immunomodulatory Immunoglobulin Therapy has been operating since 1992 at Oxford Radcliffe Hospitals in the UK. Initially, this program was set up for patients with multifocal motor neuropathy or chronic inflammatory demyelinating poly-neuropathy to receive reduced doses of intravenous immunoglobulin (IVIG) in clinic on a regular basis (usually every 3 weeks). The program then rapidly expanded to include self-infusion at home, which monitoring showed to be safe and effective. It has been since extended to the treatment of other autoimmune diseases in which IVIG has been shown to be efficacious.

Interest & Impact

Downloads

37 since deposited on 04 Oct 2013
37 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item